Migraine treatment tomorrow and the day after tomorrow. Impact on the CGRP pathway


DOI: https://dx.doi.org/10.18565/pharmateca.2019.13.58-62

K.V. Skorobogatykh, Yu.E. Azimova

University Headache Clinic, Moscow, Russia
Migraine is a chronic neurological disease characterized by a high prevalence and a significant decrease in quality of life. The combination of these factors leads to a significant negative socio-economic impact. Recently, significant progress has been made in understan-ding the pathogenesis of migraine, which led to the emergence of new classes of drugs for the treatment of this disease. This review discusses the history of the study of calcitonin gene - related peptide (CGRP) in the pathogenesis of migraine, and the characteristics of new drugs that affect the pathway of CGRP receptor antagonists (“gepants”) and monoclonal antibodies against CGRP/CGRP receptor.
Keywords: migraine, CGRP, calcitonin gene-related peptide, gepants, monoclonal antibodies

About the Autors


Corresponding author: Kirill V. Skorobogatykh, University Headache Clinic, Moscow, Russia; e-mail: post.kirill@gmail.com
Address: 2, build. 1, Molodogvardeiskaya Street, Moscow 121467, Russian Federation


Бионика Медиа